Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis

Company Overview

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways. The company conducts clinical trials both domestically and internationally, working with regulatory agencies in the United States and Europe. Through strategic collaborations, Karyopharm seeks to expand the therapeutic reach of its SINE technology into other areas of oncology and potentially neurodegenerative diseases.

Karyopharm is led by Michael Kauffman, M.D., President and Chief Executive Officer, who co-founded the company and has guided its transition from preclinical research to commercial-stage operations. Under his leadership, Karyopharm has forged partnerships with global pharmaceutical firms to advance pipeline candidates and ensure broader patient access. The company maintains a scientific advisory board composed of experts in cancer biology, translational medicine and drug development.

Key Stats

• Today's Range: $1.76 to $1.84
• 50-Day Range: $1.77 to $10.67
• 52-Week Range: $1.72 to $10.99
• Volume: 577,293 shs
• Average Volume: 1.27 million shs
• Market Capitalization: $40.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Moderate Buy

Karyopharm Therapeutics Stock Analysis - MarketRank™

Karyopharm Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 502nd out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Karyopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Karyopharm Therapeutics has a consensus price target of $11.50, representing about 542.5% upside from its current price of $1.79.

Amount of Analyst Coverage

Karyopharm Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($4.70) to ($2.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Karyopharm Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Karyopharm Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

43.23% of the float of Karyopharm Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Karyopharm Therapeutics has a short interest ratio ("days to cover") of 4.46.

Change versus previous month

Short interest in Karyopharm Therapeutics has recently increased by 27.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Karyopharm Therapeutics does not currently pay a dividend.

Dividend Growth

Karyopharm Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.14

News Sentiment

Karyopharm Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Karyopharm Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38.00 in company stock.

Percentage Held by Insiders

1.68% of the stock of Karyopharm Therapeutics is held by insiders.

Percentage Held by Institutions

66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/05/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:KPTI
• CIK: 1503802
• Web: www.karyopharm.com
• Phone: (617) 658-0600
• Fax: N/A
• Employees: 380
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Karyopharm Therapeutics: $11.50
• High Price Target: $28.00
• Low Price Target: $3.00
• Potential Upside/Downside: +542.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($13.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$196.04 million
• Net Margins: -153.28%
• Pretax Margin: -153.30%
• Return on Equity: N/A
• Return on Assets: -145.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.79
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $146.07 million
• Price / Sales: 0.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($14.56) per share
• Price / Book: -0.12

Miscellaneous

• Outstanding Shares: 22,680,000
• Free Float: 22,300,000
• Market Cap: $40.60 million
• Optionable: Optionable
• Beta: 0.95